A retrospective study of oral adverse events with colorectal cancer chemotherapy using bevacizumab

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 6, 2011, Pages 959-962

  Takahashi, Hiroko ^a   Sato, Miyuki ^a   Tsukada, Kou ^a   Tsuchiya, Setsuo ^a   Tanda, Shigeru ^a  

^a TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Bevacizumab; Oral mucositis; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DENTAL CARIES; DENTURE; DIABETES MELLITUS; FEMALE; FOOT AND MOUTH DISEASE; HUMAN; MALE; MOUTH DISEASE; MOUTH HYGIENE; MOUTH ULCER; MYCOSIS; ORAL MUCOSITIS; ORAL PSEUDOMEMBRANE; PERIODONTAL DISEASE; RISK FACTOR;

EID: 84867031169     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Croom KF and Foster RH: Bevacizumab in the treatment of colorectal cancer. Am J Cancer 3(3): 187-194, 2004.
2. Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3): 671-680, 2005.
3. Clarkson JE, Worthington HV and Eden OB: Interventions for treating oral mucositis for patients with cancer receiving treatment. Aust Dent J 53(4): 363-365, 2008.
4. Sonis ST: Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5(9): 3-11, 2007.
5. http://www.info.pmda.go.jp/juutoku/file/jfm0905011.pdf
6. Upile T, Jerjes W, Kafas P, et al: Salivary VEGF: a non-invasive angiogenic and lymphangiogenic proxy in head and neck cancer prognostication. Int Arch Med 2(1): 12, 2009.
7. Brozovic S, Vucicevic-Boras V, Mravak-Stipetic M, et al: Salivary levels of vascular endothelial growth factor (VEGF) in recurrent aphthous ulceration. J Oral Pathol Med 31(2): 106-108, 2002. (Pubitemid 34535996)
8. Bao P, Kodra A, Tomic-Canic M, et al: The role of vascular endothelial growth factor in wound healing. J Surg Res 153(2): 347-358, 2009.